Ki-ras mutations as a prognostic factor in extrahepatic bile system cancer

Núria Malats, Miquel Porta, Josep L. Piñol, Josep M. Corominas, Juli Rifà, Francisco X. Real

Research output: Contribution to journalArticleResearchpeer-review

51 Citations (Scopus)


Purpose: To assess the prevalence and prognostic significance of Ki-ras codon 12 mutations in extrahepatic biliary system cancer (EBSC). Patients and Methods: Patients diagnosed with EBSC between 1980 and 1990 (N = 111) were selected from two hospitals. DNA was amplified from paraffin-embedded tissues and mutations in codon 12 of Ki-ras were detected using the artificial restriction fragment-length polymorphism (RFLP) technique. Results: Tissue was available from 68.5% of patients. The prevalence of mutations was 41%. There was no association between mutations and clinical and pathologic characteristics; however, mutations in Ki-ras were associated with survival, with a median survival duration of 7.7 months for patients with wild-type Ki- ras and 1.7 months for patients with mutated tumors (hazards ratio [HR] = 1.67; P = .075). Among patients with stage I to II tumors, the chance of dying of patients with the mutation was 7.8 times higher than that of patients without the mutation (P = .087); the corresponding HR for patients with stage III to IV disease was 2.9 (P = .003). After adjusting for age, tumor site, histology, differentiation, and stage, the HR for Ki-ras mutations was 2.12 (P = .026). Conclusion: Ki-ras codon 12 mutations are an independent prognostic indicator in patients with EBSC. Mutation detection may be of help in the management of these patients.
Original languageEnglish
Pages (from-to)1679-1686
JournalJournal of Clinical Oncology
Issue number7
Publication statusPublished - 1 Jan 1995


Dive into the research topics of 'Ki-ras mutations as a prognostic factor in extrahepatic bile system cancer'. Together they form a unique fingerprint.

Cite this